Few peptide pairings get searched as often as the “Wolverine stack.” The name borrows from the Marvel character known for healing almost instantly, and it refers to two research peptides that are frequently studied side by side: BPC-157 and TB-500. Online, the stack is often surrounded by bold claims and very little context. This guide sets the hype aside and explains what each compound is, how the two differ at the molecular level, why researchers pair them, and what the published research actually shows so far.
At Wolverine Peptide, both compounds are supplied strictly for laboratory research. They are not intended for human or veterinary use, and nothing in this article should be read as medical advice.
What is the Wolverine stack?
The Wolverine stack is an informal name for pairing BPC-157 with TB-500 in tissue-repair research. The logic behind the pairing is that the two peptides appear to work through different biological pathways. BPC-157 is usually discussed in terms of local tissue effects and blood vessel signalling, while TB-500 is discussed in terms of cell migration and its movement through tissues.
It is important to understand that the Wolverine stack is a nickname, not a regulated product category or a defined protocol. Some suppliers sell the two compounds pre-blended in one vial, often at a 1:1 ratio. Others, including us, supply them as separate single-compound vials. Separate vials make it possible to verify each compound against its own certificate of analysis, and they give researchers full control over ratios and study design.
What is BPC-157?
BPC-157 stands for Body Protection Compound-157. It is a synthetic pentadecapeptide, which simply means a chain of 15 amino acids. Its sequence is derived from a protein fragment found naturally in human gastric juice. In the scientific literature it also appears under other names, including PL 14736, PL-10 and Bepecin.
One feature that has drawn research interest is its stability. Unlike many peptides, BPC-157 has been reported to remain relatively stable in gastric conditions, which is unusual for a molecule of this type. Much of the early work on it came from a research group in Zagreb, Croatia, which has published extensively on the compound over several decades.
Key research areas for BPC-157 include:
- Tendon, ligament and muscle healing models in rodents
- Gastrointestinal mucosal protection and ulcer models
- Angiogenesis, the formation of new blood vessels
- Interaction with the nitric oxide (NO) signalling system
- Wound healing in skin and cornea models
What is TB-500?
TB-500 is a synthetic peptide based on the active region of thymosin beta-4, a naturally occurring 43-amino-acid protein found in almost all human and animal cells. Thymosin beta-4 plays a role in regulating actin, a protein that forms part of the cell’s internal skeleton and helps cells move.
Because of this link to actin, thymosin beta-4 has been studied for its role in cell migration, the formation of new blood vessels, and soft-tissue repair. Researchers have looked at it in wound, cardiac and eye injury models, among others.
There is one important nuance that often gets lost online. Much of the published research was carried out on full-length thymosin beta-4, not on TB-500 itself. TB-500 is frequently assumed to behave in the same way, but it has not been independently validated to the same degree. Any researcher reviewing the literature should keep that distinction in mind.
BPC-157 vs TB-500: side-by-side
| BPC-157 | TB-500 | |
| Origin | Fragment of a gastric juice protein | Based on thymosin beta-4 |
| Length | 15 amino acids | Synthetic analog of a 43-amino-acid protein |
| Main research focus | Local tissue repair, GI protection, angiogenesis | Cell migration, actin regulation, wider tissue repair |
| Evidence base | Mostly rodent and cell studies; very limited human data | Mostly animal and cell studies on thymosin beta-4 |
| Wolverine Peptide format | 10 mg lyophilized vial | 10 mg lyophilized vial |
Why researchers study them together
The main rationale for pairing is complementary mechanisms. BPC-157 research points toward local effects and angiogenesis signalling. Thymosin beta-4 research points toward cell motility and broader tissue distribution. In theory, one compound works close to the site of injury while the other supports the movement of repair cells.
Studying both in the same model lets researchers ask useful questions. Do the two pathways overlap? Are their effects additive? Does one interfere with the other? These questions can only be answered with carefully controlled experiments that include single-compound arms alongside the combination.
That said, direct peer-reviewed studies of the combination are scarce. Most of what circulates online about “synergy” is extrapolated from single-compound work, and should be treated as a hypothesis rather than an established finding.
What the research does and doesn’t show
The honest summary is that the evidence base is still early-stage:
- Most BPC-157 findings come from rodent and in-vitro studies. Human data is limited to a small retrospective report on knee pain and an early safety study whose results were not fully published.
- A 2025 literature review in Pharmaceuticals summarised BPC-157’s proposed mechanisms and highlighted the gap between animal findings and human evidence. That review also sparked a published rebuttal from the original research group, which shows the science is still actively debated.
- There are no large, well-controlled human trials for TB-500.
For a research lab, this uncertainty makes compound quality even more important. When the literature is thin, every dataset carries more weight. A contaminated, degraded or mislabeled vial can quietly ruin months of work and produce results that nobody can reproduce.
Quality checks before starting a study
Before running any experiment with BPC-157 or TB-500, confirm the following:
- The vial’s lot number matches the lot number on the COA.
- HPLC purity is at or above 98–99%, with the chromatogram shown.
- Mass spectrometry confirms the correct molecular weight.
- Endotoxin screening is reported, which is especially important for cell work.
- The vial arrived cold and has been stored correctly since.
Our full walkthrough is here: How to Read a Peptide COA. If you are still comparing suppliers, our guide on where to buy Wolverine peptides covers what to verify before ordering.
Legal status
Neither BPC-157 nor TB-500 is an FDA-approved drug. Their status on the FDA’s compounding lists changed significantly in 2026, and the process is still ongoing. We cover the full timeline in Is BPC-157 Legal in 2026?
FAQ
Is the Wolverine stack a single product?
No. It is a nickname for BPC-157 and TB-500 studied together. They can be supplied as one blend or as two separate vials.
Which is better for research, BPC-157 or TB-500?
Neither is “better.” They are studied for different mechanisms, so the right choice depends on the research question being asked.
Why buy separate vials instead of a blend?
Separate vials allow each compound to be verified against its own COA and give researchers control over ratios.
Are BPC-157 and TB-500 approved for human use?
No. Neither is an FDA-approved drug.